A Phase IIb Randomized, Double-blind, Controlled Study of the Safety, Immunogenicity and Proof-of-concept of RTS,S/AS02D, a Candidate Malaria Vaccine, When Incorporated Into an Expanded Program on Immunization (EPI) Regimen That Includes DTPw/Hib in Infants Living in a Malaria-endemic Region

Trial Profile

A Phase IIb Randomized, Double-blind, Controlled Study of the Safety, Immunogenicity and Proof-of-concept of RTS,S/AS02D, a Candidate Malaria Vaccine, When Incorporated Into an Expanded Program on Immunization (EPI) Regimen That Includes DTPw/Hib in Infants Living in a Malaria-endemic Region

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs GSK 257049 (Primary) ; Hepatitis B vaccine recombinant; Hib-DTP vaccine; Poliovirus vaccine live oral
  • Indications Diphtheria; Falciparum malaria; Haemophilus infections; Hepatitis B; Influenza B virus infections; Malaria; Pertussis; Poliomyelitis; Tetanus
  • Focus Adverse reactions; Pharmacodynamics; Proof of concept; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 09 Mar 2010 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
    • 11 Dec 2008 Results have been published in the New England Journal of Medicine.
    • 09 Dec 2008 Results presented at the American Society for Tropical Medicine and Hygeine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top